Andrew Wahba and Rafik ElBeblawy. Three Novel HSPG2 Mutations Causing Schwartz-Jampel Syndrome.
. 2020; 8(10):325-327. doi: 10.12691/AJMCR-8-10-1
Schwartz-Jampel syndrome, heparan sulfate proteoglycan 2, HSPG2, myotonia
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Katirji B. Chapter 17 - Peripheral nerve hyperexcitability. In: Levin KH, Chauvel P, eds. Handbook of Clinical Neurology. Vol 161. Elsevier; 2019: 281-290. |
|
[2] | SCHWARTZ O, JAMPEL RS. Congenital Blepharophimosis Associated with a Unique Generalized Myopathy. Archives of Ophthalmology. 1962; 68(1): 52-57. |
|
[3] | Preston DC, Shapiro BE. 36 - Myotonic Muscle Disorders and Periodic Paralysis Syndromes. In: Preston DC, Shapiro BE, eds. Electromyography and Neuromuscular Disorders (Third Edition). London: W.B. Saunders; 2013: 563-582. |
|
[4] | Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. The Journal of Clinical Investigation. 1998; 102(8): 1599-1608. |
|
[5] | Nicole S, Davoine C-S, Topaloglu H, et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nature Genetics. 2000; 26(4): 480-483. |
|
[6] | Peng HB, Xie H, Rossi SG, Rotundo RL. Acetylcholinesterase Clustering at the Neuromuscular Junction Involves Perlecan and Dystroglycan. Journal of Cell Biology. 1999; 145(4): 911-921. |
|
[7] | Arikawa-Hirasawa E, Wilcox WR, Le AH, et al. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nature Genetics. 2001; 27(4): 431-434. |
|
[8] | Arikawa-Hirasawa E, Le AH, Nishino I, et al. Structural and Functional Mutations of the Perlecan Gene Cause Schwartz-Jampel Syndrome, with Myotonic Myopathy and Chondrodysplasia. The American Journal of Human Genetics. 2002; 70(5): 1368-1375. |
|
[9] | Giedion A, Boltshauser E, Briner J, et al. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. European journal of pediatrics. 1997; 156: 214-223. |
|
[10] | Viljoen D, Beighton P. Schwartz-Jampel syndrome (chondrodystrophic myotonia). Journal of Medical Genetics. 1992; 29(1): 58-62. |
|
[11] | Stum M, Davoine C-S, Vicart S, et al. Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome. Human Mutation. 2006; 27(11): 1082-1091. |
|
[12] | Mathur N, Ghosh PS. Schwartz-Jampel Syndrome. Pediatric Neurology. 2017; 68: 77-78. |
|
[13] | Regalo SC, Vitti M, Semprini M, et al. The effect of the Schwartz-Jampel syndrome on masticatory and facial musculatures--an electromyographic analysis. Electromyogr Clin Neurophysiol. 2005; 45(3): 183-189. |
|
[14] | Narayanaswami P. 17 - Treatment and Management of Disorders of Neuromuscular Hyperexcitability. In: Bertorini TE, ed. Neuromuscular Disorders: Treatment and Management. Saint Louis: W.B. Saunders; 2011: 285-306. |
|
[15] | Iwata S, Ito M, Nakata T, et al. A missense mutation in domain III in HSPG2 in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space. Neuromuscul Disord. 2015; 25(8): 667-671. |
|
[16] | Das Bhowmik A, Dalal A, Matta D, Kandadai RM, Kanikannan MA, Aggarwal S. Identification of a novel splice site HSPG2 mutation and prenatal diagnosis in Schwartz Jampel Syndrome type 1 using whole exome sequencing. Neuromuscul Disord. 2016; 26(11): 809-814. |
|
[17] | Yan W, Dai J, Shi D, et al. Novel HSPG2 mutations causing Schwartz-Jampel syndrome type 1 in a Chinese family: A case report. Mol Med Rep. 2018; 18(2): 1761-1765. |
|